As many as 200 former GlaxoSmithKline employees who were transferred to life science services firm Parexel earlier this year are reportedly being laid off today. However, the Boston-based company which has a large presence in the Triangle, isn’t talking.

“In general, we do not discuss any employee-related matters to ensure the privacy for our employees and confidentiality for our clients,” said Diana Martin, vice president of corporate communications for Parexel (Nasdaq: PRXL), via email.

A month ago, Parexel said it was cutting 850 jobs but did not specify where the cuts would be made.

Parexel provides a variety of services, such as the conduct of drug clinical trials. The GSK transfers at least temporarily doubled the size of Parexel’s Triangle work force.

In February, GSK (NYSE: GSK) said it planned to transfer several hundred Triangle workers to Parexel as part of a cost-cutting move. Some 900 jobs are being cut in the Triangle, including 450 workers shifted to Parexel under a negotiated agreement.

However, on Wednesday morning, many of those workers who still are based at a GSK building in RTP began being called in for one-on-one meetings as the layoffs started.

A former Parexel/GSK worker who recently left the firm for another job has remained in contact with former co-workers said coleagues had “confirmed” that “a couple hundred people do all have their 5 [minute] meetings in person today with Parexel [human resources] in the Sanders building where we have been working (on GSK’s campus) to find out their futures.”

The reported cuts are the latest in a series that have hit GSK, Hospira, Salix and Merck as well as technology firms such as Lenovo and NetApp.

Parexel Chairman and CEO Josef von Rickenbach announced the layoff plan during meetings with investors at the company’s Boston headquarters in June, calling it a “Margin Acceleration Program.”

“As we finish Fiscal Year 2015 and look ahead to Fiscal Year 2016, we believe that we have good momentum, a strong and diversified backlog, and a healthy business development pipeline,” Rickenbach said.

“Our priorities for the new year include solid revenue growth, as well as improved operating profitability and double-digit growth in earnings per share. In conjunction with our new guidance we are also raising our long-term adjusted operating margin target from 12%-14% of service revenue to 13%-15% of service revenue.  We are accelerating a number of our ongoing improvement plans, and as a result of these efforts, plan to restructure certain activities.  We believe that this will strengthen the Company by increasing our competitiveness in the marketplace, and will help us to deliver long-term sustainable growth in revenue and margins.”

Parexel said the job cuts would cost the company some $60 million once they were completed in July.